ACADIA Pharmaceuticals Inc DR6.BE
€22.68
Last Updated: Dec 17, 12:00 AM·BE
Pricing for DE stocks is delayed by 24 hours
DR6.BE Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, ACADIA Pharmaceuticals Inc is classified as halal.
HALAL
Report Source: undefined Quarter Report
ACADIA Pharmaceuticals Inc. Stock Analysis DR6.BE
Germany Health Care Mid Cap ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. The company is headquartered in San Diego, California and currently employs 653 full-time employees. The company went IPO on 2004-05-27. The company develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. The company has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.
ACADIA Pharmaceuticals Inc (DR6.BE) Chart
Financial Metrics & Statements of ACADIA Pharmaceuticals Inc (DR6.BE)
FAQ's for ACADIA Pharmaceuticals Inc (DR6.BE)
- As of August 2026, ACADIA Pharmaceuticals Inc DR6.BE is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes ACADIA Pharmaceuticals Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in ACADIA Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of ACADIA Pharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of ACADIA Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of ACADIA Pharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Related Halal Stocks to ACADIA Pharmaceuticals Inc (DR6.BE)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
